Introduction to the analysis of PET data in oncology

Journal of Pharmacokinetics and Pharmacodynamics

Volumn 40, Issue 4, 2013, Pages 419-436

  Tomasi, Giampaolo ^a   Aboagye, Eric O ^a  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

Author keywords

Movement correction; Oncology; Partial volume correction; PET; Textural features

Indexed keywords

1 FLUORO 3 (2 NITRO 1 IMIDAZOLYL) 2 PROPANOL F 18; 16ALPHA FLUOROESTRADIOL F 18; 16BETA FLUORO 5A DIHYDROTESTOSTERONE F 18; 3' FLUORO 3' DEOXYTHYMIDINE F 18; CARBON LEUCINE C 11; CARBON TYROSINE C 11; COPPER DIACETYL BIS(N4 METHYLTHIOSEMICARBAZONE) CU 64; FLUCICLOVINE F 18; FLUORO ARGINYLGLYCYLASPARTIC ACID F 18; FLUORODEOXYGLUCOSE F 18; FLUOROURACIL; METHIONINE C 11; RADIOPHARMACEUTICAL AGENT; TAMOXIFEN; TEMOZOLOMIDE; TRASTUZUMAB; UNCLASSIFIED DRUG;

CANCER PROGNOSIS; CANCER SURVIVAL; ESOPHAGUS CANCER; HEAD AND NECK CANCER; HUMAN; IMAGE ANALYSIS; IMAGE ENHANCEMENT; IMAGE PROCESSING; IMAGE QUALITY; IMAGING AND DISPLAY; IMAGING SOFTWARE; ISOTOPE LABELING; LUNG NON SMALL CELL CANCER; MEDICAL PARAMETERS; MOLECULAR IMAGING; MOTION CORRECTION; NUCLEAR MAGNETIC RESONANCE IMAGING; ONCOLOGY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PARTIAL VOLUME EFFECT; POSITRON EMISSION TOMOGRAPHY; PREDICTION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; REVIEW; SEGMENTATION; STANDARDIZED UPTAKE VALUE; UTERINE CERVIX CANCER; WHOLE BODY IMAGING;

ANIMALS; HUMANS; NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; STATISTICS AS TOPIC;

EID: 84881184285     PISSN: 1567567X     EISSN: 15738744     Source Type: Journal    
DOI: 10.1007/s10928-013-9307-3     Document Type: Review

References (112)

1. Cherry S, Dahlbom M (2004) PET: physics, instrumentation and scanners. In: Phelps ME (ed) PET: molecular imaging and its biological applications. Springer, New York, pp 1-124
2. Bailey DL, Townsend DW, Valk PE, Maisey MN (2005) Positron emission tomography, 1st edn. Springer, London
3. van Dalen JA, Visser EP, Vogel WV, Corstens FH, Oyen WJ (2007) Impact of Ge-68/Ga-68-based versus CT-based attenuation correction on PET. Med Phys 34(3):889-897
4. Hudson HM, Larkin RS (1994) Accelerated image reconstruction using ordered subsets of projection data. IEEE Trans Med Imaging 13(4):601-609. doi: 10.1109/42.363108
5. Defrise M, Kinahan PE, Townsend DW, Michel C, Sibomana M, Newport DF (1997) Exact and approximate rebinning algorithms for 3-D PET data. IEEE Trans Med Imaging 16(2):145-158. doi: 10.1109/42.563660
6. Qi J, Leahy RM (2006) Iterative reconstruction techniques in emission computed tomography. Phys Med Biol 51(15):R541-R578. doi: 10.1088/0031-9155/51/ 15/R01
7. Fessler JA, Rogers WL (1996) Spatial resolution properties of penalized-likelihood image reconstruction: space-invariant tomographs. IEEE Trans Image Process 5(9):1346-1358. doi: 10.1109/83.535846
8. Boellaard R, Krak NC, Hoekstra OS, Lammertsma AA (2004) Effects of noise, image resolution, and ROI definition on the accuracy of standard uptake values: a simulation study. J Nucl Med 45(9):1519-1527
9. Bailey DL, Meikle SR (1994) A convolution-subtraction scatter correction method for 3D PET. Phys Med Biol 39(3):411-424
10. Grootoonk S, Spinks TJ, Sashin D, Spyrou NM, Jones T (1996) Correction for scatter in 3D brain PET using a dual energy window method. Phys Med Biol 41(12):2757-2774
11. Erlandsson K, Buvat I, Pretorius PH, Thomas BA, Hutton BF (2012) A review of partial volume correction techniques for emission tomography and their applications in neurology, cardiology and oncology. Phys Med Biol 57(21):R119-R159. doi: 10.1088/0031-9155/57/21/R119
12. Soret M, Bacharach SL, Buvat I (2007) Partial-volume effect in PET tumor imaging. J Nucl Med 48(6):932-945. doi: 10.2967/jnumed.106.035774
13. Soret MRC, Hapdey S, Buvat I (2002) Biases affecting the measurements of tumor-to-background activity ratio in PET. IEEE Trans Nucl Sci 49:2112-2118
14. Le Pogam A, Hatt M, Descourt P, Boussion N, Tsoumpas C, Turkheimer FE, Prunier-Aesch C, Baulieu JL, Guilloteau D, Visvikis D (2011) Evaluation of a 3D local multiresolution algorithm for the correction of partial volume effects in positron emission tomography. Med Phys 38(9):4920-4923. doi: 10.1118/1.3608907
15. Shidahara M, Tsoumpas C, Hammers A, Boussion N, Visvikis D, Suhara T, Kanno I, Turkheimer FE (2009) Functional and structural synergy for resolution recovery and partial volume correction in brain PET. Neuroimage 44(2):340-348. doi: 10.1016/j.neuroimage.2008.09.012
16. Muller-Gartner HW, Links JM, Prince JL, Bryan RN, McVeigh E, Leal JP, Davatzikos C, Frost JJ (1992) Measurement of radiotracer concentration in brain gray matter using positron emission tomography: mRI-based correction for partial volume effects. J Cereb Blood Flow Metab 12(4):571-583. doi: 10.1038/jcbfm.1992.81
17. Boussion N, Cheze Le Rest C, Hatt M, Visvikis D (2009) Incorporation of wavelet-based denoising in iterative deconvolution for partial volume correction in whole-body PET imaging. Eur J Nucl Med Mol Imaging 36(7):1064-1075. doi: 10.1007/s00259-009-1065-5
18. Formiconi AR (1993) Least squares algorithm for region-of-interest evaluation in emission tomography. IEEE Trans Med Imaging 12(1):90-100. doi: 10.1109/42.222672
19. Videen TO, Perlmutter JS, Mintun MA, Raichle ME (1988) Regional correction of positron emission tomography data for the effects of cerebral atrophy. J Cereb Blood Flow Metab 8(5):662-670. doi: 10.1038/jcbfm.1988.113
20. Hutton BF, Thomas BA, Erlandson K, Bousse A, Reilhac-Laborde A, Kazantsev D, Pedemonte S, Vunckx K, Arridge SR, Ourselin S (2012) What approach to brain partial volume correction is best for PET/MRI? Nucl Instrum Methods. doi: 10.1016/j.nima.2012.07.059
21. Curiati PK, Tamashiro-Duran JH, Duran FL, Buchpiguel CA, Squarzoni P, Romano DC, Vallada H, Menezes PR, Scazufca M, Busatto GF, Alves TC (2011) Age-related metabolic profiles in cognitively healthy elders: results from a voxel-based [18F]fluorodeoxyglucose-positron-emission tomography study with partial volume effects correction. AJNR Am J Neuroradiol 32(3):560-565. doi: 10.3174/ajnr.A2321
22. Yanase D, Matsunari I, Yajima K, Chen W, Fujikawa A, Nishimura S, Matsuda H, Yamada M (2005) Brain FDG PET study of normal aging in Japanese: effect of atrophy correction. Eur J Nucl Med Mol Imaging 32(7):794-805. doi: 10.1007/s00259-005-1767-2
23. Lamare F, Cresson T, Savean J, Cheze Le Rest C, Reader AJ, Visvikis D (2007) Respiratory motion correction for PET oncology applications using affine transformation of list mode data. Phys Med Biol 52(1):121-140. doi: 10.1088/0031-9155/52/1/009
24. Nehmeh SA, Erdi YE, Ling CC, Rosenzweig KE, Squire OD, Braban LE, Ford E, Sidhu K, Mageras GS, Larson SM, Humm JL (2002) Effect of respiratory gating on reducing lung motion artifacts in PET imaging of lung cancer. Med Phys 29(3):366-371
25. Landoni C, Bettinardi V, Guerra L, De Ponti E, Fioroni F, Elisei F, Picchio M, Versari A, Gianolli L, Messa C (2010) 4D Respiratory-gated (RG) FDG-PET/CT in neoplastic patients: results of a multicenter study. J Nucl Med 51(Supplement 2):1171
26. Rahmim A, Rousset O, Zaidi H (2007) Strategies for motion tracking and correction in PET. PET Clin 2(2):251-266
27. Kyme AZ, Hutton BF, Hatton RL, Skerrett DW, Barnden LR (2003) Practical aspects of a data-driven motion correction approach for brain SPECT. IEEE Trans Med Imaging 22(6):722-729. doi: 10.1109/TMI.2003.814790
28. Mourik JE, Lubberink M, van Velden FH, Lammertsma AA, Boellaard R (2009) Off-line motion correction methods for multi-frame PET data. Eur J Nucl Med Mol Imaging 36(12):2002-2013. doi: 10.1007/s00259-009-1193-y
29. Kenny LM, Contractor KB, Hinz R, Stebbing J, Palmieri C, Jiang J, Shousha S, Al-Nahhas A, Coombes RC, Aboagye EO (2010) Reproducibility of [11C]choline-positron emission tomography and effect of trastuzumab. Clin Cancer Res 16(16):4236-4245. doi: 10.1158/1078-0432.CCR-10-0468
30. Nye JA, Esteves F, Votaw JR (2007) Minimizing artifacts resulting from respiratory and cardiac motion by optimization of the transmission scan in cardiac PET/CT. Med Phys 34(6):1901-1906
31. Smith G, Carroll L, Aboagye EO (2012) New frontiers in the design and synthesis of imaging probes for PET oncology: current challenges and future directions. Mol Imaging Biol 14(6):653-666. doi: 10.1007/s11307-012-0590-y
32. Tomasi G, Turkheimer F, Aboagye E (2011) Importance of quantification for the analysis of PET data in oncology: review of current methods and trends for the future. Mol Imaging Biol. doi: 10.1007/s11307-011-0514-2
33. Wahl RL, Jacene H, Kasamon Y, Lodge MA (2009) From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors. J Nucl Med 50(Suppl 1):122S-150S. doi: 10.2967/jnumed.108.057307
34. Hutchings M, Barrington SF (2009) PET/CT for therapy response assessment in lymphoma. J Nucl Med 50(Suppl 1):21S-30S. doi: 10.2967/jnumed.108.057190
35. Hicks RJ (2009) Role of 18F-FDG PET in assessment of response in non-small cell lung cancer. J Nucl Med 50(Suppl 1):31S-42S. doi: 10.2967/jnumed.108.057216
36. de Geus-Oei LF, Vriens D, van Laarhoven HW, van der Graaf WT, Oyen WJ (2009) Monitoring and predicting response to therapy with 18F-FDG PET in colorectal cancer: a systematic review. J Nucl Med 50(Suppl 1):43S-54S. doi: 10.2967/jnumed.108.057224
37. Avril N, Sassen S, Roylance R (2009) Response to therapy in breast cancer. J Nucl Med 50(Suppl 1):55S-63S. doi: 10.2967/jnumed.108.057240
38. Schwarz JK, Grigsby PW, Dehdashti F, Delbeke D (2009) The role of 18F-FDG PET in assessing therapy response in cancer of the cervix and ovaries. J Nucl Med 50(Suppl 1):64S-73S. doi: 10.2967/jnumed.108.057257
39. Schoder H, Fury M, Lee N, Kraus D (2009) PET monitoring of therapy response in head and neck squamous cell carcinoma. J Nucl Med 50(Suppl 1):74S-88S. doi: 10.2967/jnumed.108.057208
40. Krause BJ, Herrmann K, Wieder H, zum Buschenfelde CM (2009) 18F-FDG PET and 18F-FDG PET/CT for assessing response to therapy in esophageal cancer. J Nucl Med 50(Suppl 1):89S-96S. doi: 10.2967/jnumed.108.057232
41. Herrmann K, Wieder HA, Buck AK, Schoffel M, Krause BJ, Fend F, Schuster T, Meyer zum Buschenfelde C, Wester HJ, Duyster J, Peschel C, Schwaiger M, Dechow T (2007) Early response assessment using 3′-deoxy-3′-[18F] fluorothymidine-positron emission tomography in high-grade non-Hodgkin's lymphoma. Clin Cancer Res 13(12):3552-3558. doi: 10.1158/1078-0432.CCR-06-3025
42. Troost EG, Bussink J, Hoffmann AL, Boerman OC, Oyen WJ, Kaanders JH (2010) 18F-FLT PET/CT for early response monitoring and dose escalation in oropharyngeal tumors. J Nucl Med 51(6):866-874. doi: 10.2967/jnumed.109.069310
43. Contractor KB, Kenny LM, Stebbing J, Rosso L, Ahmad R, Jacob J, Challapalli A, Turkheimer F, Al-Nahhas A, Sharma R, Coombes RC, Aboagye EO (2011) [18F]-3′Deoxy-3′-fluorothymidine positron emission tomography and breast cancer response to docetaxel. Clin Cancer Res 17(24):7664-7672. doi: 10.1158/1078-0432.CCR-11-0783
44. Pio BS, Park CK, Pietras R, Hsueh WA, Satyamurthy N, Pegram MD, Czernin J, Phelps ME, Silverman DH (2006) Usefulness of 3′-[F-18]fluoro-3′- deoxythymidine with positron emission tomography in predicting breast cancer response to therapy. Mol Imaging Biol 8(1):36-42. doi: 10.1007/s11307-005-0029-9
45. Chen W, Delaloye S, Silverman DH, Geist C, Czernin J, Sayre J, Satyamurthy N, Pope W, Lai A, Phelps ME, Cloughesy T (2007) Predicting treatment response of malignant gliomas to bevacizumab and irinotecan by imaging proliferation with [18F] fluorothymidine positron emission tomography: a pilot study. J Clin Oncol 25(30):4714-4721. doi: 10.1200/JCO.2006.10.5825
46. Kasper B, Egerer G, Gronkowski M, Haufe S, Lehnert T, Eisenhut M, Mechtersheimer G, Ho AD, Haberkorn U (2007) Functional diagnosis of residual lymphomas after radiochemotherapy with positron emission tomography comparing FDG- and FLT-PET. Leuk Lymphoma 48(4):746-753. doi: 10.1080/10428190601113568
47. Nanni C, Fantini L, Nicolini S, Fanti S (2010) Non FDG PET. Clin Radiol 65(7):536-548. doi: 10.1016/j.crad.2010.03.012
48. Boellaard R (2009) Standards for PET image acquisition and quantitative data analysis. J Nucl Med 50(Suppl 1):11S-20S. doi: 10.2967/jnumed.108.057182
49. Williams SP, Flores-Mercado JE, Baudy AR, Port RE, Bengtsson T (2012) The power of FDG-PET to detect treatment effects is increased by glucose correction using a Michaelis constant. EJNMMI Res 2(1):35. doi: 10.1186/2191-219X-2-35
50. Cheebsumon P, Velasquez LM, Hoekstra CJ, Hayes W, Kloet RW, Hoetjes NJ, Smit EF, Hoekstra OS, Lammertsma AA, Boellaard R (2011) Measuring response to therapy using FDG PET: semi-quantitative and full kinetic analysis. Eur J Nucl Med Mol Imaging 38(5):832-842. doi: 10.1007/s00259-010-1705-9
51. Lubberink M, Direcks W, Emmering J, van Tinteren H, Hoekstra OS, van der Hoeven JJ, Molthoff CF, Lammertsma AA (2012) Validity of simplified 3′-deoxy-3′-[(18)F]fluorothymidine uptake measures for monitoring response to chemotherapy in locally advanced breast cancer. Mol Imaging Biol. doi: 10.1007/s11307-012-0547-1
52. Ferl GZ, Zhang X, Wu HM, Kreissl MC, Huang SC (2007) Estimation of the 18F-FDG input function in mice by use of dynamic small-animal PET and minimal blood sample data. J Nucl Med 48(12):2037-2045. doi: 10.2967/jnumed.107.041061
53. Zheng X, Wen L, Yu SJ, Huang SC, Feng DD (2012) A study of non-invasive Patlak quantification for whole-body dynamic FDG-PET studies of mice. Biomed Signal Process Control 7(5):438-446. doi: 10.1016/j.bspc.2011.11.005
54. Paesmans M, Berghmans T, Dusart M, Garcia C, Hossein-Foucher C, Lafitte JJ, Mascaux C, Meert AP, Roelandts M, Scherpereel A, Terrones Munoz V, Sculier JP (2010) Primary tumor standardized uptake value measured on fluorodeoxyglucose positron emission tomography is of prognostic value for survival in non-small cell lung cancer: update of a systematic review and meta-analysis by the European Lung Cancer Working Party for the International Association for the Study of Lung Cancer Staging Project. J Thorac Oncol 5(5):612-619. doi: 10.1097/JTO.0b013e3181d0a4f5
55. Agarwal M, Brahmanday G, Bajaj SK, Ravikrishnan KP, Wong CY (2010) Revisiting the prognostic value of preoperative (18)F-fluoro-2-deoxyglucose ((18)F-FDG) positron emission tomography (PET) in early-stage (I & II) non-small cell lung cancers (NSCLC). Eur J Nucl Med Mol Imaging 37(4):691-698. doi: 10.1007/s00259-009-1291-x
56. Hyun SH, Choi JY, Shim YM, Kim K, Lee SJ, Cho YS, Lee JY, Lee KH, Kim BT (2010) Prognostic value of metabolic tumor volume measured by 18F-fluorodeoxyglucose positron emission tomography in patients with esophageal carcinoma. Ann Surg Oncol 17(1):115-122. doi: 10.1245/s10434-009-0719-7
57. Choi JY, Jang HJ, Shim YM, Kim K, Lee KS, Lee KH, Choi Y, Choe YS, Kim BT (2004) 18F-FDG PET in patients with esophageal squamous cell carcinoma undergoing curative surgery: prognostic implications. J Nucl Med 45(11):1843-1850. doi: 45/11/1843
58. Blackstock AW, Farmer MR, Lovato J, Mishra G, Melin SA, Oaks T, Aklilu M, Clark PB, Levine EA (2006) A prospective evaluation of the impact of 18-F-fluoro-deoxy-d-glucose positron emission tomography staging on survival for patients with locally advanced esophageal cancer. Int J Radiat Oncol Biol Phys 64(2):455-460. doi: 10.1016/j.ijrobp.2005.07.959
59. Cheze-Le Rest C, Metges JP, Teyton P, Jestin-Le Tallec V, Lozac'h P, Volant A, Visvikis D (2008) Prognostic value of initial fluorodeoxyglucose-PET in esophageal cancer: a prospective study. Nucl Med Commun 29(7):628-635. doi: 10.1097/MNM.0b013e3282f81423
60. Bryant AS, Cerfolio RJ, Klemm KM, Ojha B (2006) Maximum standard uptake value of mediastinal lymph nodes on integrated FDG-PET-CT predicts pathology in patients with non-small cell lung cancer. Ann Thorac Surg 82(2):417-422; discussion 422-413. doi: 10.1016/j.athoracsur.2005.12.047
61. Rizk N, Downey RJ, Akhurst T, Gonen M, Bains MS, Larson S, Rusch V (2006) Preoperative 18[F]-fluorodeoxyglucose positron emission tomography standardized uptake values predict survival after esophageal adenocarcinoma resection. Ann Thorac Surg 81(3):1076-1081. doi: 10.1016/j.athoracsur.2005.09.063
62. Yu H, Caldwell C, Mah K, Mozeg D (2009) Coregistered FDG PET/CT-based textural characterization of head and neck cancer for radiation treatment planning. IEEE Trans Med Imaging 28(3):374-383
63. Tixier F, Le Rest CC, Hatt M, Albarghach N, Pradier O, Metges JP, Corcos L, Visvikis D (2011) Intratumor heterogeneity characterized by textural features on baseline 18F-FDG PET images predicts response to concomitant radiochemotherapy in esophageal cancer. J Nucl Med 52(3):369-378. doi: 10.2967/jnumed.110.082404
64. El Naqa I, Grigsby P, Apte A, Kidd E, Donnelly E, Khullar D, Chaudhari S, Yang D, Schmitt M, Laforest R, Thorstad W, Deasy JO (2009) Exploring feature-based approaches in PET images for predicting cancer treatment outcomes. Pattern Recognit 42(6):1162-1171. doi: 10.1016/j.patcog.2008.08.011
65. Eary JF, O'Sullivan F, O'Sullivan J, Conrad EU (2008) Spatial heterogeneity in sarcoma 18F-FDG uptake as a predictor of patient outcome. J Nucl Med 49(12):1973-1979. doi: 10.2967/jnumed.108.053397
66. Tixier F, Hatt M, Le Rest CC, Le Pogam A, Corcos L, Visvikis D (2012) Reproducibility of tumor uptake heterogeneity characterization through textural feature analysis in 18F-FDG PET. J Nucl Med 53(5):693-700. doi: 10.2967/jnumed.111.099127
67. Galavis PE, Hollensen C, Jallow N, Paliwal B, Jeraj R (2010) Variability of textural features in FDG PET images due to different acquisition modes and reconstruction parameters. Acta Oncol 49(7):1012-1016. doi: 10.3109/0284186X. 2010.498437
68. Vaidya M, Creach KM, Frye J, Dehdashti F, Bradley JD, El Naqa I (2012) Combined PET/CT image characteristics for radiotherapy tumor response in lung cancer. Radiother Oncol 102(2):239-245. doi: 10.1016/j.radonc.2011.10.014
69. Willaime JM, Turkheimer FE, Kenny LM, Aboagye EO (2013) Quantification of intra-tumour cell proliferation heterogeneity using imaging descriptors of 18F fluorothymidine-positron emission tomography. Phys Med Biol 58(2):187-203. doi: 10.1088/0031-9155/58/2/187
70. Gunn RN, Gunn SR, Cunningham VJ (2001) Positron emission tomography compartmental models. J Cereb Blood Flow Metab 21(6):635-652. doi: 10.1097/00004647-200106000-00002
71. Kety SS, Schmidt CF (1948) The nitrous oxide method for the quantitative determination of cerebral blood flow in man; theory, procedure and normal values. J Clin Invest 27(4):476-483
72. Sokoloff L, Reivich M, Kennedy C, Des Rosiers MH, Patlak CS, Pettigrew KD, Sakurada O, Shinohara M (1977) The [14C]deoxyglucose method for the measurement of local cerebral glucose utilization: theory, procedure, and normal values in the conscious and anesthetized albino rat. J Neurochem 28(5):897-916
73. Mintun MA, Raichle ME, Kilbourn MR, Wooten GF, Welch MJ (1984) A quantitative model for the in vivo assessment of drug binding sites with positron emission tomography. Ann Neurol 15(3):217-227. doi: 10.1002/ana.410150302
74. Logan J, Fowler JS, Volkow ND, Wolf AP, Dewey SL, Schlyer DJ, MacGregor RR, Hitzemann R, Bendriem B, Gatley SJ et al (1990) Graphical analysis of reversible radioligand binding from time-activity measurements applied to [N-11C-methyl]-(-)-cocaine PET studies in human subjects. J Cereb Blood Flow Metab 10(5):740-747
75. Patlak CS, Blasberg RG, Fenstermacher JD (1983) Graphical evaluation of blood-to-brain transfer constants from multiple-time uptake data. J Cereb Blood Flow Metab 3(1):1-7
76. Cunningham VJ, Jones T (1993) Spectral analysis of dynamic PET studies. J Cereb Blood Flow Metab 13(1):15-23
77. Lammertsma AA, Hume SP (1996) Simplified reference tissue model for PET receptor studies. Neuroimage 4(3 Pt 1):153-158. doi: 10.1006/nimg.1996.0066
78. Logan J, Fowler JS, Volkow ND, Wang GJ, Ding YS, Alexoff DL (1996) Distribution volume ratios without blood sampling from graphical analysis of PET data. J Cereb Blood Flow Metab 16(5):834-840. doi: 10.1097/00004647-199609000- 00008
79. Mankoff DA, Shields AF, Graham MM, Link JM, Eary JF, Krohn KA (1998) Kinetic analysis of 2-[carbon-11]thymidine PET imaging studies: compartmental model and mathematical analysis. J Nucl Med 39(6):1043-1055
80. Wells JM, Mankoff DA, Muzi M, O'Sullivan F, Eary JF, Spence AM, Krohn KA (2002) Kinetic analysis of 2-[11C]thymidine PET imaging studies of malignant brain tumors: compartmental model investigation and mathematical analysis. Mol Imaging 1(3):151-159
81. Wells JM, Mankoff DA, Eary JF, Spence AM, Muzi M, O'Sullivan F, Vernon CB, Link JM, Krohn KA (2002) Kinetic analysis of 2-[11C]thymidine PET imaging studies of malignant brain tumors: preliminary patient results. Mol Imaging 1(3):145-150
82. Tomasi G, Kimberley S, Rosso L, Aboagye E, Turkheimer F (2012) Double-input compartmental modeling and spectral analysis for the quantification of positron emission tomography data in oncology. Phys Med Biol 57(7):1889-1906. doi: 10.1088/0031-9155/57/7/1889
83. Mankoff DA, Shields AF, Graham MM, Link JM, Krohn KA (1996) A graphical analysis method to estimate blood-to-tissue transfer constants for tracers with labeled metabolites. J Nucl Med 37(12):2049-2057
84. Kenny L, Vigushin D, Al-Nahhas A, Osman S, Luthra S, Coombes C, Aboagye E (2005) Quantification of cellular proliferation in tumor and normal tissues of patients with breast cancer by [18F]fluorothymidine-positron emission tomography imaging: evaluation of analytical methods. Cancer Res 65(21):10104-10112
85. Tomasi G, Kenny L, Mauri F, Turkheimer F, Aboagye EO (2011) Quantification of receptor-ligand binding with [(18)F]fluciclatide in metastatic breast cancer patients. Eur J Nucl Med Mol Imaging. doi: 10.1007/s00259-011- 1907-9
86. Josephs D, Spicer J, O'Doherty M (2009) Molecular imaging in clinical trials. Target Oncol 4(3):151-168. doi: 10.1007/s11523-009-0117-x
87. Fowler JS, Finn RD, Lambrecht RM, Wolf AP (1973) The synthesis of 18 F-5-fluorouracil. VII. J Nucl Med 14(1):63-64
88. Saleem A, Brown GD, Brady F, Aboagye EO, Osman S, Luthra SK, Ranicar AS, Brock CS, Stevens MF, Newlands E, Jones T, Price P (2003) Metabolic activation of temozolomide measured in vivo using positron emission tomography. Cancer Res 63(10):2409-2415
89. McGuire AH, Dehdashti F, Siegel BA, Lyss AP, Brodack JW, Mathias CJ, Mintun MA, Katzenellenbogen JA, Welch MJ (1991) Positron tomographic assessment of 16 alpha-[18F] fluoro-17 beta-estradiol uptake in metastatic breast carcinoma. J Nucl Med 32(8):1526-1531
90. Inoue T, Kim EE, Wallace S, Yang DJ, Wong FC, Bassa P, Cherif A, Delpassand E, Buzdar A, Podoloff DA (1996) Positron emission tomography using [18F]fluorotamoxifen to evaluate therapeutic responses in patients with breast cancer: preliminary study. Cancer Biother Radiopharm 11(4):235-245
91. Rosso L, Brock CS, Gallo JM, Saleem A, Price PM, Turkheimer FE, Aboagye EO (2009) A new model for prediction of drug distribution in tumor and normal tissues: pharmacokinetics of temozolomide in glioma patients. Cancer Res 69(1):120-127. doi: 10.1158/0008-5472.CAN-08-2356
92. Laruelle M (2000) Imaging synaptic neurotransmission with in vivo binding competition techniques: a critical review. J Cereb Blood Flow Metab 20(3):423-451. doi: 10.1097/00004647-200003000-00001
93. Tomasi G (2011) Imaging endogenous neurotransmitters in vivo with Positron Emission Tomography displacement studies. Curr Psycopharmacol 1(1):29-43
94. Abi-Dargham A, van de Giessen E, Slifstein M, Kegeles LS, Laruelle M (2009) Baseline and amphetamine-stimulated dopamine activity are related in drug-naive schizophrenic subjects. Biol Psychiatry 65(12):1091-1093. doi: 10.1016/j.biopsych.2008.12.007
95. Hatt M, Visvikis D, Albarghach NM, Tixier F, Pradier O, Cheze-le Rest C (2011) Prognostic value of 18F-FDG PET image-based parameters in oesophageal cancer and impact of tumour delineation methodology. Eur J Nucl Med Mol Imaging 38(7):1191-1202. doi: 10.1007/s00259-011-1755-7
96. Lee NY, Mechalakos JG, Nehmeh S, Lin Z, Squire OD, Cai S, Chan K, Zanzonico PB, Greco C, Ling CC, Humm JL, Schoder H (2008) Fluorine-18-labeled fluoromisonidazole positron emission and computed tomography-guided intensity-modulated radiotherapy for head and neck cancer: a feasibility study. Int J Radiat Oncol Biol Phys 70(1):2-13. doi: 10.1016/j.ijrobp.2007.06.039
97. Sovik A, Malinen E, Olsen DR (2009) Strategies for biologic image-guided dose escalation: a review. Int J Radiat Oncol Biol Phys 73(3):650-658. doi: 10.1016/j.ijrobp.2008.11.001
98. South CP, Partridge M, Evans PM (2008) A theoretical framework for prescribing radiotherapy dose distributions using patient-specific biological information. Med Phys 35(10):4599-4611
99. Vees H, Senthamizhchelvan S, Miralbell R, Weber DC, Ratib O, Zaidi H (2009) Assessment of various strategies for 18F-FET PET-guided delineation of target volumes in high-grade glioma patients. Eur J Nucl Med Mol Imaging 36(2):182-193. doi: 10.1007/s00259-008-0943-6
100. Zaidi H, El Naqa I (2010) PET-guided delineation of radiation therapy treatment volumes: a survey of image segmentation techniques. Eur J Nucl Med Mol Imaging 37(11):2165-2187. doi: 10.1007/s00259-010-1423-3
101. Nestle U, Kremp S, Schaefer-Schuler A, Sebastian-Welsch C, Hellwig D, Rube C, Kirsch CM (2005) Comparison of different methods for delineation of 18F-FDG PET-positive tissue for target volume definition in radiotherapy of patients with non-Small cell lung cancer. J Nucl Med 46(8):1342-1348
102. Schaefer A, Kremp S, Hellwig D, Rube C, Kirsch CM, Nestle U (2008) A contrast-oriented algorithm for FDG-PET-based delineation of tumour volumes for the radiotherapy of lung cancer: derivation from phantom measurements and validation in patient data. Eur J Nucl Med Mol Imaging 35(11):1989-1999. doi: 10.1007/s00259-008-0875-1
103. Hatt M, Cheze le Rest C, Turzo A, Roux C, Visvikis D (2009) A fuzzy locally adaptive Bayesian segmentation approach for volume determination in PET. IEEE Trans Med Imaging 28(6):881-893. doi: 10.1109/TMI.2008.2012036
104. Le Maitre A, Hatt M, Pradier O, Cheze-le Rest C, Visvikis D (2012) Impact of the accuracy of automatic tumour functional volume delineation on radiotherapy treatment planning. Phys Med Biol 57(17):5381-5397. doi: 10.1088/0031-9155/57/17/5381
105. Tylski P, Stute S, Grotus N, Doyeux K, Hapdey S, Gardin I, Vanderlinden B, Buvat I (2010) Comparative assessment of methods for estimating tumor volume and standardized uptake value in (18)F-FDG PET. J Nucl Med 51(2):268-276. doi: 10.2967/jnumed.109.066241
106. Hatt M, Cheze Le Rest C, Albarghach N, Pradier O, Visvikis D (2011) PET functional volume delineation: a robustness and repeatability study. Eur J Nucl Med Mol Imaging 38(4):663-672. doi: 10.1007/s00259-010-1688-6
107. Cheebsumon P, Yaqub M, van Velden FH, Hoekstra OS, Lammertsma AA, Boellaard R (2011) Impact of [(1)F]FDG PET imaging parameters on automatic tumour delineation: need for improved tumour delineation methodology. Eur J Nucl Med Mol Imaging 38(12):2136-2144. doi: 10.1007/s00259-011-1899-5
108. Zaidi H, Abdoli M, Fuentes CL, El Naqa IM (2012) Comparative methods for PET image segmentation in pharyngolaryngeal squamous cell carcinoma. Eur J Nucl Med Mol Imaging. doi: 10.1007/s00259-011-2053-0
109. Cheebsumon P, van Velden FH, Yaqub M, Frings V, de Langen AJ, Hoekstra OS, Lammertsma AA, Boellaard R (2011) Effects of image characteristics on performance of tumor delineation methods: a test-retest assessment. J Nucl Med 52(10):1550-1558. doi: 10.2967/jnumed.111.088914
110. Hatt M, Cheze-Le Rest C, Aboagye EO, Kenny LM, Rosso L, Turkheimer FE, Albarghach NM, Metges JP, Pradier O, Visvikis D (2010) Reproducibility of 18F-FDG and 3′-deoxy-3′-18F-fluorothymidine PET tumor volume measurements. J Nucl Med 51(9):1368-1376. doi: 10.2967/jnumed.110.078501
111. Zaidi H, Abdoli M, Fuentes CL, El Naqa IM (2012) Comparative methods for PET image segmentation in pharyngolaryngeal squamous cell carcinoma. Eur J Nucl Med Mol Imaging 39(5):881-891. doi: 10.1007/s00259-011-2053-0
112. Kenny L, Coombes RC, Vigushin DM, Al-Nahhas A, Shousha S, Aboagye EO (2007) Imaging early changes in proliferation at 1 week post chemotherapy: a pilot study in breast cancer patients with 3′-deoxy-3′-[18F] fluorothymidine positron emission tomography. Eur J Nucl Med Mol Imaging 34(9):1339-1347. doi: 10.1007/s00259-007-0379-4